MWC 2024

    Eyecane AR Breakthrough: A Revolutionary Solution for Partial Retinal Blindness

    Exciting news from the world of technology: Cellico's developed Eyecane AR glasses are set to correct partial retinal blindness.

    In a groundbreaking development in the tech world, Cellico has introduced the Eyecane AR glasses at MWC 2024, marking a first in augmented reality (AR) technology for correcting partial retinal blindness.

    This innovative product specifically targets age-related macular degeneration (AMD), offering a new horizon of hope for those affected.

    Innovative Features: Resembling standard sunglasses in appearance, the Eyecane AR is equipped with a 4K camera. This camera captures the world around and projects the image onto tiny screens within the lenses of the glasses.

    Meta’s first real AR glasses are coming out this year

    For individuals suffering from AMD, this technology fills in the blind spots in their field of vision with real-time digital imagery, facilitating clear sight where it was previously hindered.

    User-Friendly Approach: One of the standout features of the Eyecane AR is its ease of use. It can be employed straight out of the box without the need for a hospital visit. The accompanying mobile app identifies the blind spots in the user’s vision field, allowing the AR glasses’ camera to focus on these areas.

    https://youtu.be/u9JNRI1MI4E?si=SPcWX4iCTJzEyeVB

    This process takes just a few minutes and rapidly restores vision in the macular region using the capabilities of augmented reality displays. This technological advancement opens new doors for those battling AMD, offering a beacon of independence and improved quality of life.

    The combination of advanced camera and display technologies in the Eyecane AR demonstrates a significant leap forward in addressing partial retinal blindness, showcasing the intersection of technology and healthcare progress.

    No comments yet Write the First Comment
    ×

    Your comment has been submitted,
    it will be published after approval.

    Write a Comment